Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT04196712
Recruiting Observational

Essen Coronary Artery Disease Registry

NCT04196712 · tracked via the Priya Life Science Germany tracker
Sponsor
University Hospital, Essen
Phase
Observational
Started
2019-09-01
Last updated
2024-12-24

Condition(s) studied

Coronary Artery Disease

Study summary

The ECAD registry is a registry of patients undergoing coronary angiography at the West German Heart and Vascular Center. The registry anticipates to determine predictors of patient outcome after coronary angiography.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing invasive coronary angiography at the West German Heart and Vascular Center Exclusion Criteria: * None

Primary outcome measure(s)

  • All-cause mortality — through study completion, an average of 3 year
    Mortality of any cause

Trial sites (1)

FacilityCityRegionStatus
University Hospital Essen Essen North Rhine-Westphalia Recruiting

More University Hospital, Essen trials in Germany

Proton vs. Photon Radiotherapy for Patients With WHO Grade 2-3 Glioma Recruiting
Optimization of Radiation Protection Through Genomic Analyses Recruiting
SURgical Registry of ENDocarditis EuRope Starting soon
Essen Amyloidosis Registry Recruiting
Theranostic PET for Target Validation and Tumor Detection Recruiting

Other trials for the same condition

COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events Active, not recruiting
Randomization of Single vs Multiple Arterial Grafts Recruiting
ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety) Recruiting
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions Recruiting
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04196712 on ClinicalTrials.gov ↗ ← All trials in Germany